Introduction:
The ICH guidelines for peptide-oligonucleotide conjugates give developers a scientifically justified framework, even though no single ICH guideline is written for this modality. Regulators expect sponsors to show which guidelines apply directly, which apply by analogy, and why.
ICH describes its guidelines as harmonized technical requirements, developed through scientific and regulatory consensus, to support the development and registration of safe, effective, and high-quality medicines. For a hybrid molecule such as a POC, that consensus has to be applied thoughtfully rather than copied from small-molecule or biologic precedent.
A POC combines two analytically complex modalities:
- The peptide portion can introduce sequence-related variants, truncations, oxidation, deamidation, or disulfide-related changes.
- The oligonucleotide portion can generate chain-shortened species, modified nucleobases, stereochemical variants, or conjugation-related impurities.
- The linker and conjugation step add their own impurities, stability risks, and safety questions.
The conjugate must therefore be evaluated as a complete molecular entity, while the quality attributes of each component are still understood individually.
At ResolveMass Laboratories Inc., a Canadian analytical CRO/CDMO specializing in mass spectrometry and complex-modality characterization, we see the strongest programs connect every stage:
Molecular design → manufacturing → analytical characterization → impurity control → stability → nonclinical safety → clinical development
This article explains which ICH guidelines matter at each stage, where their scope limits apply, and how to build a defensible, risk-based strategy.
Summary
- There is no single, dedicated ICH guideline for peptide-oligonucleotide conjugates (POCs). The ICH guidelines for peptide-oligonucleotide conjugates are an integrated framework of quality, analytical, stability, impurity, safety, and risk-management guidelines, applied to the specific molecule.
- ICH Q14 and Q2(R2) govern analytical procedure development and validation for identity, purity, impurities, degradation products, and other critical quality attributes (CQAs).
- ICH Q3 principles support impurity assessment, but scope must be checked first. Peptides and oligonucleotides do not always fit small-molecule impurity frameworks (ICH M7 states it is not intended for them).
- ICH Q5, Q5C, and Q6B become relevant when the conjugate or one of its components has biotechnology-derived characteristics.
- ICH Q8, Q9, Q10, Q11, and Q12 connect development, risk management, the quality system, drug substance control, and lifecycle management.
- ICH S6(R1) and the emerging ICH S13 shape the nonclinical strategy. S13 is a dedicated oligonucleotide safety guideline under development (concept paper endorsed November 2024).
- Orthogonal characterization (LC-MS/HRMS, peptide mapping, oligonucleotide characterization, chromatographic purity, and complementary methods) is how sponsors generate defensible evidence.
- Regional FDA and EMA guidance supplements ICH and often sets the practical expectations.
1: Why Are the ICH Guidelines for Peptide-Oligonucleotide Conjugates Important?
The ICH guidelines for peptide-oligonucleotide conjugates give developers a scientifically justified framework, even though no single ICH guideline is written for this modality. Regulators expect sponsors to show which guidelines apply directly, which apply by analogy, and why.
A POC combines two analytically complex modalities. The peptide portion can introduce sequence-related variants, truncations, oxidation, deamidation, or disulfide-related changes. The oligonucleotide portion can generate chain-shortened species, modified nucleobases, stereochemical variants, or conjugation-related impurities. The conjugate must be evaluated as a complete molecular entity, while the quality attributes of each component are still understood.
At ResolveMass Laboratories Inc., a Canadian analytical CRO/CDMO specializing in mass spectrometry and complex-modality characterization, we see the strongest programs connect every stage:
Molecular design → manufacturing → analytical characterization → impurity control → stability → nonclinical safety → clinical development
2: Which ICH Guidelines Apply to Peptide-Oligonucleotide Conjugates?
No single ICH guideline covers POCs, so developers build a risk-based, product-specific strategy from the applicable Quality, Safety, and Multidisciplinary guidelines. The table below maps each development area to the guidelines most often used.
| Development area | Relevant ICH guideline(s) | Application to conjugates |
|---|---|---|
| Analytical procedure development | Q14 | Science- and risk-based method development |
| Analytical validation | Q2(R2) | Validation of quantitative and qualitative methods |
| Impurity assessment | Q3 series (incl. Q3C, Q3D) | Evaluate applicable process and degradation impurities, solvents, and elements |
| Stability | Q1A(R2), Q5C where applicable | Stability-indicating strategy |
| Biotechnology-derived characteristics | Q5 series | Characterization and comparability where applicable |
| Specifications | Q6A / Q6B | Scientifically justified specifications |
| Quality risk management | Q9 | Risk-based CQA and control strategy |
| Pharmaceutical development | Q8 | Linking process and formulation variables to CQAs |
| Quality system | Q10 | Lifecycle quality system across sponsor and CDMO sites |
| Drug substance manufacturing | Q11 | Development and control of the drug substance |
| Lifecycle management | Q12 | Managing post-approval changes |
| Nonclinical safety | S6(R1), M3(R2), related guidance | Product-specific nonclinical strategy |
| Oligonucleotide safety | S13 (in development) | Emerging dedicated framework |
| Dossier and bioanalysis | M4 (CTD), M10 | Submission structure and bioanalytical validation |
3: How Does ICH Q14 Apply to Peptide-Oligonucleotide Conjugate Analytics?
ICH Q14 supports a science- and risk-based approach to analytical procedure development, so each method is fit for its intended purpose. This matters for POCs because no single technique describes the full quality profile.
A Q14-oriented strategy starts by defining what each method must do:
- Identity confirmation and assay
- Purity and related substances
- Conjugation efficiency
- Degradation monitoring and stability-indicating testing
- Process impurity and residual starting material monitoring
- Structural characterization
For example, LC-MS can provide molecular-mass information, chromatographic separation can reveal closely related impurities, and high-resolution mass spectrometry can help investigate unexpected components. Prior knowledge, analytical target profiles, method parameter risk assessment, and lifecycle management should all be documented.
4: What Does ICH Q2(R2) Require for Analytical Validation?
ICH Q2(R2) is the current harmonized framework for demonstrating that an analytical procedure is suitable for its intended purpose. For POCs, validation should follow the intended use of each method rather than applying one validation package to everything.
Relevant performance characteristics include:
- Specificity/selectivity
- Accuracy
- Precision and intermediate precision
- Detection and quantitation limits
- Linearity and range
- Robustness, where applicable
Q2(R2) also allows development data, prior knowledge, and risk-based approaches to contribute to the validation strategy. Well-characterized standards are central to this work, and our guidance on reference standards and analytical method validation covers how qualification and validation fit together.
| Analytical objective | Potential technique |
|---|---|
| Intact molecular mass | LC-HRMS |
| Peptide sequence confirmation | Enzymatic digestion + LC-MS/MS |
| Oligonucleotide sequence/identity | LC-MS/HRMS and complementary characterization |
| Purity/related substances | RP-HPLC/UPLC |
| Conjugation assessment | LC-MS/HRMS |
| Peptide modifications | Peptide mapping |
| Oligonucleotide impurities | Ion-pair LC, LC-MS, or orthogonal methods |
| Higher-order/physical properties | Spectroscopic or biophysical methods |
The final method selection should reflect the molecule, its intended use, its degradation pathways, and the resolution required.
5: How Should ICH Q3 Impurity Principles Be Applied?
ICH Q3 principles give a useful framework for impurity assessment, but developers must first confirm whether the specific guideline and thresholds apply to the conjugate. Do not automatically apply small-molecule thresholds to a complex peptide or oligonucleotide modality.
POCs can contain several impurity classes:
Peptide-related: deletion sequences, truncated peptides, oxidized or deamidated species, epimerized variants, aggregates or fragments.
Oligonucleotide-related: N-1 or N+1 chain-length variants, incomplete sequences, modified nucleobase species, backbone-related variants, diastereomers, and depurination or other degradation products.
Conjugation-related: unconjugated peptide, unconjugated oligonucleotide, over-conjugated species, incorrect conjugation-site variants, linker-related impurities, and hydrolyzed or modified linker species.
Residual solvents and elements: ICH Q3C and Q3D remain relevant for solvents from synthesis, cleavage, and purification, and for catalysts or metals from conjugation chemistry.
ICH M7 explicitly states that its mutagenic-impurity framework is not intended for peptide or oligonucleotide drug substances and products. Many sponsors still use its principles to screen small-molecule reagents and linker fragments, and that rationale should be documented in the CMC section.
6: How Does ICH Q11 Shape Drug Substance Development and Control?
ICH Q11 requires a documented link between process parameters, material attributes, and CQAs, which forms the backbone of a POC control strategy. Together with Q8 (pharmaceutical development) and Q10 (quality system), it defines how the drug substance is understood and controlled.
Practical expectations include:
- Defining starting materials (peptide and oligonucleotide intermediates) and justifying where GMP begins
- Identifying critical process parameters for conjugation (stoichiometry, pH, temperature, reaction time)
- Demonstrating that purification clears free peptide, free oligonucleotide, and truncated species
- Linking the control strategy to CQAs with supporting data
These expectations carry into manufacturing. Our overview of GMP manufacturing of peptide-oligonucleotide conjugates explains how process control, documentation, and quality oversight come together for clinical supply.
7: Why Are ICH Q5 Guidelines Relevant to Some Conjugates?
ICH Q5 guidelines matter when the product, or one of its components, falls within the biotechnology/biological framework. The Q5 family covers viral safety, expression construct characterization, stability, comparability, and specifications. Q5E, for example, addresses comparability after manufacturing-process changes.
Applicability depends on how the conjugate is made and regulated. Where Q5 principles apply, they become especially important during:
- Process scale-up and manufacturing-site changes
- Raw-material, linker, or conjugation-process changes
- Purification or formulation changes
- Post-approval manufacturing changes
A comparability strategy should evaluate whether a change affects CQAs, not rely on a single assay result. Scale-up and site-transfer planning is covered further in our article on GMP manufacturing considerations for peptide-oligonucleotide conjugates.
8: How Do ICH Q1A(R2) and Q5C Support Stability Testing?
ICH Q1A(R2) sets the general stability design, and Q5C provides principles for biotechnology/biological products that are useful where the conjugate has biologic-like sensitivity. The program should be built around known and potential degradation pathways of the peptide, the oligonucleotide, and the linker.
Possible stability-indicating measurements:
- Intact mass and conjugation integrity
- Peptide-related and oligonucleotide-related impurities
- Linker stability
- Aggregation or fragmentation
- Potency or biological activity
- Appearance, pH, and other physical properties
A single purity method may miss meaningful change, because degradation can occur through several mechanisms without a large shift in the main chromatographic peak. Forced degradation studies help confirm method specificity and map degradation pathways. Container closure compatibility also matters, and sponsors should follow ICH Q3E, which remained a draft guideline as of mid-2026.
9: What Role Does ICH Q6B Play in Specifications?
ICH Q6B provides principles for setting specifications for biotechnology/biological products and is useful when the conjugate falls within its scope. Specifications should link to meaningful quality attributes rather than list every measurable parameter.
Typical categories for a complex conjugate:
- Identity
- Purity
- Impurities
- Quantity/assay
- Biological activity
- Physicochemical characteristics
- Product-related variants
Support for the specification strategy should come from development data, process capability, analytical capability, stability data, and an understanding of how each attribute relates to product performance. Q6A and Q6B are the major specification guidelines for chemical and biotechnology/biological products, respectively, and POCs often draw on both by analogy.
10: How Should ICH Q9 Risk Management Support Conjugate Development?
ICH Q9 provides the risk-management framework to prioritize the quality and development risks that matter most. A practical chain is: molecular structure → potential failure mode → impact → analytical detectability → control strategy.
| Potential risk | Possible consequence | Analytical response |
|---|---|---|
| Incomplete conjugation | Reduced active conjugate | LC-MS/UPLC |
| Peptide oxidation | New related substance | Peptide mapping/LC-MS |
| Oligonucleotide truncation | Sequence-related impurity | LC-MS/oligonucleotide LC |
| Linker cleavage | Loss of conjugation | Intact LC-MS |
| Aggregation | Physical instability | Size/aggregation method |
| Degradation during storage | Reduced purity/potency | Stability-indicating methods |
This keeps the analytical program from becoming a set of disconnected tests. Every major method should answer a defined development question.
Why Is Orthogonal Characterization Important for POCs?
Orthogonal characterization is essential because POCs can contain closely related species that one technique cannot resolve. The aim is complementary evidence that together establishes identity, purity, structural integrity, and stability.
A practical panel may combine:
- LC-MS/HRMS for molecular-mass confirmation and investigation of unexpected species
- Peptide mapping for peptide sequence confirmation and peptide-specific modifications
- Oligonucleotide characterization for sequence integrity, truncations, and related species
- Chromatographic purity methods to separate and quantify related substances
- Spectroscopic and biophysical methods for conformation, aggregation, and physical properties, including NMR-based structural elucidation where atomic-level structural information is needed
What Is the Status of ICH Guidance for Oligonucleotide Therapeutics?
A dedicated ICH S13 guideline on nonclinical safety evaluation of oligonucleotide-based therapeutics is under development, which signals the growing regulatory weight of oligonucleotide-specific considerations. The S13 concept paper, endorsed in November 2024, notes that oligonucleotides differ from small molecules and biopharmaceuticals in pharmacokinetics, off-target effects, and species selection.
For POCs, S13 may become especially relevant because the conjugated peptide or targeting moiety can change distribution, cellular uptake, pharmacology, and safety. Until S13 is final and implemented, developers should use existing ICH guidelines together with justified, product-specific approaches.
How Does ICH S6(R1) Apply to Conjugated Products?
ICH S6(R1) sets principles for nonclinical safety evaluation of biotechnology-derived pharmaceuticals and stresses a product-specific, science-based approach. It does not recommend automatically applying standard safety batteries, and it describes cases where conventional genotoxicity or carcinogenicity testing may not be appropriate.
For conjugates, the strategy should address:
- Biological activity and species relevance
- Target expression and immunogenicity
- Pharmacokinetics and tissue distribution
- Linker-related and conjugate-specific toxicity
S6(R1) specifically identifies an organic linker in a conjugated product as a circumstance that may warrant consideration of genotoxic potential. Distribution data are central to interpreting safety findings, so early work on pharmacokinetics and biodistribution should be planned alongside the nonclinical package. The strategy should reflect the actual structure and mechanism, not just a “peptide” or “oligonucleotide” label.
What Regional Guidance Supplements ICH for POCs?
FDA and EMA oligonucleotide-specific documents supplement ICH and often define the practical expectations for conjugates. Examples include FDA’s clinical pharmacology recommendations for oligonucleotide therapeutics (June 2024) and its draft nonclinical safety guidance for oligonucleotide-based therapeutics (November 2024), along with EMA reflection papers and pharmacopoeial standards.
Treat ICH as the harmonized baseline and regional guidance as the detail layer. When they point to different expectations, raise the question in a pre-IND or scientific advice meeting. For a fuller view of how agencies approach this class, see our summary of the regulation of peptide-oligonucleotide conjugates.
11: What Does a Practical ICH-Aligned Development Strategy Look Like?
An effective strategy connects molecular understanding, analytical characterization, impurity control, stability, and nonclinical assessment into one risk-based program. A workable sequence:
- Define the molecular structure and quality target product profile (Q8)
- Identify CQAs and risk-rank peptide, oligonucleotide, and conjugation steps (Q9)
- Map potential peptide, oligonucleotide, and conjugation-related impurities (Q3 principles, Q3C, Q3D)
- Develop orthogonal analytical methods (Q14)
- Validate applicable methods (Q2(R2))
- Establish the control strategy, impurity approach, and specifications (Q11, Q6A/Q6B)
- Run stability-indicating and forced degradation studies (Q1A(R2), Q5C)
- Evaluate process and formulation changes using risk-based comparability (Q5E, Q12)
- Build the nonclinical package (S6(R1), M3(R2), S13 as it develops)
- Assemble the CTD with clear rationale for any out-of-scope guidelines (M4)
Every test is then tied to a defined quality or safety question, which makes the package easier to defend.
12: Common Mistakes When Applying ICH Guidelines to POCs
The most common mistakes are citing out-of-scope guidelines without justification, relying on one analytical method, and deferring impurity characterization. Each can trigger information requests or delays.
- Treating Q3A/B or M7 thresholds as automatically applicable
- Characterizing only the whole conjugate without resolving peptide-side and oligonucleotide-side impurities
- Validating methods before understanding degradation pathways
- Overlooking linker chemistry in stability, impurity, and safety assessments
- Starting GMP manufacturing before the control strategy is defined
Why Work With ResolveMass Laboratories Inc.?
ResolveMass Laboratories Inc. is a Canadian analytical CRO/CDMO with deep experience in biosimilar characterization, mass spectrometry, and complex-modality analysis. Our scientists design orthogonal method panels, run forced degradation and stability programs, and prepare data in CTD-ready formats aligned with FDA, Health Canada, and EMA expectations. Work runs under documented quality systems with data integrity controls and traceable reporting, so sponsors can defend their approach to reviewers.
If you need help mapping ICH guidelines to a specific conjugate, contact ResolveMass Laboratories Inc. to discuss scope and timelines.
Conclusion:
The ICH guidelines for peptide-oligonucleotide conjugates work best as a product-specific, risk-based framework rather than a single document. Q14 and Q2(R2) anchor analytical development and validation. Q3, Q5, and Q6B guide impurity and specification decisions once scope is confirmed. Q8, Q9, Q10, Q11, and Q12 tie development to control and lifecycle, while S6(R1) and the emerging S13 shape nonclinical safety. A defensible program shows how structure, manufacturing, CQAs, methods, degradation pathways, stability, and safety connect.
For analytical development, LC-MS/HRMS, peptide mapping, oligonucleotide characterization, chromatographic purity methods, and orthogonal techniques provide the evidence needed to understand a complex conjugate
Frequently Asked Questions:
ICH Q9 supports quality risk management. It can be used to identify critical quality attributes, potential failure modes, analytical risks, and process-related risks. For a peptide-oligonucleotide conjugate, this can help prioritize risks such as incomplete conjugation, sequence variants, linker degradation, oxidation, and other degradation pathways.
Potential critical quality attributes include molecular identity, peptide and oligonucleotide sequence integrity, conjugation efficiency, purity, related substances, molecular mass, linker integrity, potency or biological activity, and stability. The actual CQAs should be established based on the specific molecule and its mechanism of action.
ICH S6(R1) may be relevant when the product falls within the scope of biotechnology-derived pharmaceuticals. Its applicability depends on the nature and origin of the product. Developers should assess the complete molecular structure and biological characteristics before determining which nonclinical principles are appropriate.
ICH S13 is an emerging guideline focused on the nonclinical safety evaluation of oligonucleotide-based therapeutics. Its development reflects the increasing use of oligonucleotide medicines and the need for guidance that considers their distinct pharmacological and safety characteristics. Its relevance to a peptide-oligonucleotide conjugate will depend on the final scope and characteristics of the product.
Reference
- Christensen JK, Colletti N, Hooshfar S, Jiang R, Kuo C, Lindmark B, Lumen A, Youssef AS, Albertolle M, Aluri KC, Chen L. Translational and clinical development of therapeutic siRNA and ASOs: current industry practices, perspectives, and recommendations. Nucleic Acids Research. 2025 Oct 14;53(18):gkaf778.https://academic.oup.com/nar/article-pdf/doi/10.1093/nar/gkaf778/64426161/gkaf778.pdf
- Jou AF, Hainline KM. Consideration for immunogenicity assay development for oligonucleotide therapeutics. Bioanalysis. 2026 Jul 25:1-5.https://www.tandfonline.com/doi/abs/10.1080/17576180.2026.2695220
- Sinha A. CMC Support for Peptide-Oligonucleotide Conjugates (POCs) [Internet].https://resolvemass.ca/cmc-services-for-peptide-oligonucleotide-conjugates/
- Klabenkova K, Fokina A, Stetsenko D. Chemistry of peptide-oligonucleotide conjugates: a review. Molecules. 2021 Sep 6;26(17):5420.https://www.mdpi.com/1420-3049/26/17/5420
- Darji P. Impurity Profiling in Peptide-Oligonucleotide Conjugates: Identification & Control Strategies.https://resolvemass.ca/peptide-oligonucleotide-conjugates-impurity-profiling/
About the Author
